• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical and experimental allergy : >Specialist-based treatment reduces the severity of allergic rhinitis
【24h】

Specialist-based treatment reduces the severity of allergic rhinitis

机译：基于专家的治疗降低了过敏性鼻炎的严重程度

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Although the treatment of allergic rhinitis (AR) is now well established, its impact on severity has not yet been evaluated. Objective: The aim was to analyse specialist-based treatment on AR severity, nasal symptoms and quality of life. Methods: A longitudinal observational, prospective, multi-centre study with 4 weeks of follow-up was carried out by 141 allergologists and ENT specialists in Spain. Selection criteria were adult patients with AR, clinically diagnosed at least 2 years before, with a total nasal symptom score (TNSS) ≥5, not receiving either antihistamines within the previous week or nasal corticosteroids during the 2 previous weeks. Disease severity using both original Allergic Rhinitis and its Impact on Asthma (o-ARIA) and modified (m-ARIA) classifications, nasal symptoms, and Quality of Life (ESPRINT-15), were measured at baseline and after 4 weeks of treatment. Results: Among the recruited AR patients (n = 707, 58% women), 39.3% were intermittent and 60.7% persistent, 40.2% had asthma and 61.4% conjunctivitis. Most patients were treated with second generation antihistamines in monotherapy (63.2%) or in combination with intranasal corticosteroids (31.5%). While using o-ARIA, 96.9% of patients had 'moderate/severe' AR, the m-ARIA discriminated between 'moderate' (55.4%) and severe (41.5%) AR, at baseline. After 4 weeks of treatment, improvement was found on disease severity (P < 0.0001), TNSS (8.2 ± 1.8 vs. 3.5 ± 2.3, P < 0.0001) and Quality of Life (ESPRINT-15 global score: 3.0 ± 1.2 vs. 1.1 ± 1.0, P < 0.0001). Conclusions: Specialist-based treatment reduces AR severity, evaluated using the m-ARIA classification for the first time, in addition to the improvement of nasal symptoms and quality of life. Clinical relevance: Specialist-based treatment improves AR severity, in addition to nasal symptoms and quality of life. However, no matter the treatment option some AR patients remain severe and need further follow-up.
机译：背景：尽管过敏性鼻炎（AR）的治疗方法目前已经很成熟，但尚未评估其对严重性的影响。目的：目的是分析基于专家的AR严重程度，鼻部症状和生活质量的治疗方法。方法：西班牙的141名过敏学家和耳鼻喉专科医生进行了一项纵向观察，前瞻性，多中心研究，为期4周的随访。选择标准为成人AR患者，其临床诊断至少在2年之前，总鼻症状评分（TNSS）≥5，在前一周内未接受抗组胺药或在前2周内未接受过鼻皮质激素治疗。在基线和治疗4周后，使用原始过敏性鼻炎及其对哮喘的影响（o-ARIA）和改良的（m-ARIA）分类，鼻部症状和生活质量（ESPRINT-15）来测量疾病严重程度。结果：在入选的AR患者（n = 707，女性中58％）中，间歇性39.3％，持续性60.7％，哮喘40.2％，结膜炎61.4％。大多数患者在单一疗法中（63.2％）或与鼻内皮质类固醇激素结合（31.5％）接受了第二代抗组胺药的治疗。在使用o-ARIA时，有96.9％的患者患有“中度/重度” AR，在基线时，m-ARIA区分为“中度”（55.4％）和重度（41.5％）AR。治疗4周后，发现疾病严重程度（P <0.0001），TNSS（8.2±1.8 vs. 3.5±2.3，P <0.0001）和生活质量（ESPRINT-15总体得分：3.0±1.2 vs. 1.1）有改善。 ±1.0，P <0.0001）。结论：基于专家的治疗可降低AR严重程度，这是首次使用m-ARIA分类进行评估，此外还改善了鼻部症状和生活质量。临床意义：除鼻部症状和生活质量外，基于专家的治疗还改善了AR的严重程度。但是，无论采用何种治疗方法，一些AR患者仍然很严重，需要进一步随访。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号